Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment

doi:10.4239/wjd.v13.i2.85

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7510)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

558

WORD

147

HTML

4528

Tables (1-4)

313

Sum=5546

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

323

Download

718

Sum=1041

Publishing Process of This Article

Item

Count

Browse

285

Download

638

Sum=923

Feb 15, 2022 (publication date) through Dec 21, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Feb 15, 2022; 13(2): 85-96
Published online Feb 15, 2022. doi: 10.4239/wjd.v13.i2.85

Table 4 Cardiovascular outcome trials with dipeptidyl peptidase 4 inhibitors

	CVOT	Comparator	Cardiovascular safety (MACE) (HR)	Risk of hospitalization for heart failure (HR)
Alogliptin	EXAMINE	Placebo	0.96	1.07
Linagliptin	CARMELINA	Placebo	1.02	0.90
Linagliptin	CAROLINA	Glimepiride	0.98	1.21
Saxagliptin	SAVOR-TIMI	Placebo	1.00	1.27
Sitagliptin	TECOS	Placebo	0.98	1.00

CVOT: Cardiovascular outcome trial; HR: Hazard ratio; MACE: Major adverse cardiovascular events.

Citation: Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes 2022; 13(2): 85-96
URL: https://www.wjgnet.com/1948-9358/full/v13/i2/85.htm
DOI: https://dx.doi.org/10.4239/wjd.v13.i2.85